PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy
نویسندگان
چکیده
PReS-FINAL-2156: Analysis of gene expression and inflammation biomarkers in systemic juvenile idiopathic arthritis (SJIA) patients on canakinumab therapy N Nirmala, N Wulffraat, H Brunner, P Quartier, R Brik, L Mccann, H Ozdogan, L Rutkowska-Sak, R Schneider, V Gerloni, L Harel, M Terreri, K Houghton, R Joos, D Kingsbury, J Lopez-Benitez, S Radominski, A Brachat, S Bek, M Schumacher, M Valentin, H Gram, K Abrams, A Martini, N Ruperto, D Lovell, PRINTO/PRCSG
منابع مشابه
Gene-expression analysis of adult-onset Still’s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity
BACKGROUND Adult-onset Still's disease (AOSD), a rare autoinflammatory disorder, resembles systemic juvenile idiopathic arthritis (SJIA). The superimposable systemic clinical features of AOSD and SJIA suggest both clinical phenotypes represent the same disease continuum with different ages of onset. To further characterize the similarity between AOSD and SJIA at the molecular level, 2 previousl...
متن کاملPReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
Methods Data from the 3 trials done as part of the phase III program were pooled for this analysis. Pts aged 2-19 yrs with active SJIA were enrolled and received subcutaneous CAN 4 mg/kg or placebo. The post-hoc analysis presented here focuses on SJIA response to CAN therapy in the initial treatment period of a total of 178 CAN-naïve pts. Methodological factors precluded a comparator group, so ...
متن کاملPReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients
Introduction Canakinumab (CAN), a selective, fully human, antiinterleukin-1b monoclonal antibody, has been shown to be efficacious in SJIA patients (pts) in 2 phase 3 trials: Trial 1 (4-wk, randomized placebo [PBO]-controlled) and Trial 2 (open-label CAN treatment [Part 1] followed by a randomized PBO-controlled withdrawal phase [Part 2]). In Trial 1, statistically significantly more CAN than P...
متن کاملEarly changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy
BACKGROUND Canakinumab is a human anti-interleukin-1β (IL-1β) monoclonal antibody neutralizing IL-1β-mediated pathways. We sought to characterize the molecular response to canakinumab and evaluate potential markers of response using samples from two pivotal trials in systemic juvenile idiopathic arthritis (SJIA). METHODS Gene expression was measured in patients with febrile SJIA and in matche...
متن کاملGenes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
Introduction Adult-onset Still’s disease (AOSD) is a rare auto-inflammatory disorder resembling a similar pediatric syndrome known as systemic juvenile idiopathic arthritis (SJIA).[1] The superimposable systemic and clinical features in SJIA and AOSD suggest that both clinical phenotypes represent a disease continuum with a pediatric (SJIA) and more adult-onset (AOSD).[2] Analyses of gene expre...
متن کامل